In the fourth quarter of 2008, Zyprexa sales totaled $1.147 billion, a 10 percent decrease compared with the fourth quarter of 2007. U.S. sales of Zyprexa decreased 4 percent to $584.0 million, driven by lower demand caused in part by variations in wholesaler buying patterns, partially offset by increased net effective selling prices. Zyprexa sales in international markets decreased 15 percent, to $562.7 million, driven by decreased demand, the unfavorable impact of foreign exchange rates, and, to a lesser extent, lower prices. Demand outside the U.S. was unfavorably impacted by generic competition in Germany and Canada, partially offset by growth in Japan. As noted above, generic olanzapine has been withdrawn from the German market.
For the full-year of 2008, worldwide Zyprexa sales decreased 1 percent to $4.696 billion. U.S. Zyprexa sales for 2008 were $2.203 billion, a 1 percent decrease driven by lower demand, partially offset by higher prices. Zyprexa sales outside the U.S. were $2.494 billion, a 1 percent decrease driven by lower demand and decreased selling prices, partially offset by the favorable impact of foreign exchange rates.
For the fourth quarter of 2008, Cymbalta generated $721.2 million in
sales, an increase of 15 percent compared with the fourth quarter of 2007.
U.S. sales of Cymbalta increased 10 percent, to $602.7 million, driven
primarily by higher demand and, to a lesser extent, increased prices. Sales
outside the U.S. were $118.5 million, an increase of 46 percent, driven
primarily by higher demand, partially offset by the unfavorable impact of
foreign exchange rates. Higher demand outside the U.S. reflects both increased
demand in established markets, as well as recent launches in new markets
including France, Canada a
|SOURCE Eli Lilly and Company|
Copyright©2009 PR Newswire.
All rights reserved